The objective of the present study was to compare the mechanical, kinetic, and biochemical properties of fibrin clots produced using EVICEL Fibrin Sealant (Human) and TISSEEL Fibrin Sealant. The stiffness/elasticity and strength of fibrin clots formed with EVICEL and TISSEEL were assessed using applied mechanical force and thromboelastography (TEG). The factor XIII content of the fibrin clots was also evaluated. Mean Young modulus and tensile strength of the fibrin clots produced by EVICEL were significantly higher than those of clots produced by TISSEEL (P < 0.05 for both). The mean time to initial clot formation and mean time to the predefined level of clot formation were numerically shorter for EVICEL compared with TISSEEL. Furthermore, mean maximal amplitude of the clots formed with EVICEL was significantly greater than that for the clots formed with TISSEEL. Mean concentration of factor XIII for the EVICEL fibrinogen samples tested was 9 IU/ml compared with undetectable concentrations of factor XIII for the TISSEEL fibrinogen samples. Fibrin clots formed with EVICEL have a much higher resistance to stretching and tensile strength and are more capable of maintaining their structure against applied force than those formed with TISSEEL. EVICEL also allows more rapid development of fibrin clots than TISSEEL. This superior clot strength and resilience obtained with EVICEL relative to TISSEEL may be due in large part to the presence of factor XIII. Blood Coagul
Introduction
A number of fibrin sealants are commercially available, typically consisting of human plasma-derived thrombin and fibrinogen, which are combined and applied to a target bleeding site to achieve hemostasis [1] . Efficacy of these agents has been demonstrated in a variety of surgical settings, including cardiac, thoracic, plastic and reconstructive, gastrointestinal, orthopedic, and neurologic surgery [2] [3] [4] [5] [6] [7] [8] [9] .
EVICEL Fibrin Sealant (Human) (Johnson & Johnson
Wound Management, a division of ETHICON, INC., Somerville, New Jersey, USA), which contains only human components and no aprotinin or tranexamic acid, is indicated as an adjunct for hemostasis in patients undergoing surgery, when control of bleeding by standard surgical techniques is ineffective or impractical [10] . EVICEL is a modification of CROSSEAL Fibrin Sealant (Human) (Johnson & Johnson Wound Management, a division of ETHICON, INC.), in which the plasminogen component has been removed by affinity chromatography using tranexamic acid ligand, alleviating the need for an antifibrinolytic agent, such as aprotinin or tranexamic acid [11] .
In contrast, TISSEEL Fibrin Sealant (Baxter Healthcare Corporation, Westlake Village, California, USA) contains plasminogen and synthetic aprotinin [12] . The inclusion of aprotinin is intended to prevent plasmin and plasminogen-mediated fibrinogen and clot degradation and therefore increase the shelf-life stability and the longevity and integrity of the clot by preventing premature fibrinolysis [11] .
Previously, the only study [13] comparing EVICEL Fibrin Sealant (Human) and TISSEEL Fibrin Sealant was a biomechanical performance comparison regarding strength of repair following the utilization of the two products following the suture repair of experimentally transected nerves. Nerve sections treated with EVI-CEL Fibrin Sealant (Human), TISSEEL Fibrin Sealant, or DuraSeal polyethylene glycol sealant (Confluent Surgical, Inc., Waltham, Massachusetts, USA) demonstrated significantly greater resistance to gapping than the control group (no treatment; P < 0.01 for all comparisons); no differences were observed between active treatments.
No other published studies to date have compared the physicochemical properties of fibrin clots formed following application of EVICEL Fibrin Sealant (Human) with those formed with other commercially available fibrin sealants. The present study was therefore designed to compare the mechanical, kinetic, and biochemical properties of the fibrin clots produced using EVICEL Fibrin Sealant (Human) and TISSEEL Fibrin Sealant. This study was funded by OMRIX Biopharmaceuticals R&D, Israel; editorial support for this manuscript was funded by ETHICON, Inc. The authors were not compensated and retained full editorial control over the content of the manuscript.
Methods
Preparation of fibrin sealants EVICEL Fibrin Sealant (Human) was supplied as a kit consisting of the following two separate components: one vial each of BAC2 (55-85 mg/ml fibrinogen) and thrombin (800-1200 IU/ml human thrombin) frozen solutions [10] . These components were thawed prior to use.
TISSEEL Fibrin Sealant was supplied as a kit consisting of two prefilled syringes that contained a sealer protein solution (67-106 mg/ml fibrinogen and 2250-3750 IU/ml synthetic aprotinin) and a thrombin solution [400-625 IU/ml thrombin (human) diluted in calcium chloride] [12] .
Young modulus and tensile strength testing
The Young modulus (also known as the modulus of elasticity, a measure of the force required to change the shape of a fibrin clot by a predefined amount) and the tensile strength (the maximal force applied prior to failure/breakage) of fibrin clots were measured using a motor-driven tension and compression tester (LF Plus Tensile Machine, Lloyd Instruments, Fareham, UK), using a method similar to that previously reported by Velada and colleagues [14] .
Fibrin clots for testing were created with EVICEL Fibrin Sealant (Human) or TISSEEL Fibrin Sealant using casts designed for testing in an elongation test. Each cast comprised two conical parts. The upper part was mounted with its narrow end facing downwards on top of the lower part with its narrow end facing upwards, forming a dumbbell shape. The aluminum casts were coated with Vaseline for sealing. The casts were placed on a hard surface lubricated with Vaseline. The two solutions for each fibrin sealant were drawn into separate 5-ml syringes and then injected together into the casts. The casts were filled to the top with approximately 1.5 ml of combined solutions and then incubated at 378C for 30 min to allow adequate polymerization. Three batches of fibrin clots (with five to six casts in each batch) were formed in this manner for each fibrin sealant.
Each cast was mounted on the LF Plus Tensile Machine and mechanically pulled apart, with the upper part of the cast moving away from the lower part. The testing was performed using the NEXYGEN PLUS software program (Lloyd Instruments) with an extension speed of 12.7 mm/min until failure of the fibrin clot. The force exerted (y) during the test was plotted vs. the distance travelled (x). The slopes of these stress-strain curves were used to calculate the Young modulus value; the maximal force measured prior to the clot yield was determined as the tensile strength of the clot.
Thromboelastography
The mechanical strength, shear elasticity, and formation kinetics of the fibrin clots produced by EVICEL Fibrin Sealant (Human) and TISSEEL Fibrin Sealant were assessed with a Thrombelastograph (TEG) Hemostasis Analyzer (Model 5000; Haemoscope Corporation, Niles, Illinois, USA). Prior to testing, the fibrinogen component of each sealant kit was diluted 1 : 20 and 1 : 30 (125 mmol/l NaCl/10 mmol/l sodium citrate, pH 7.1) to obtain a concentration measurable by TEG. Clot formation was initiated with the addition of 20 ml of 10 IU/ml (prediluted in 40 mmol/l CaCl 2 ) of the thrombin component of EVICEL Fibrin Sealant (Human) or TISSEEL Fibrin Sealant to 340 ml of the corresponding fibrinogen component of the fibrin sealant. The analysis was performed according to manufacturer's instructions; each sample was measured for approximately 30 min. Three fibrin clots were formed and assessed in this manner for each fibrin sealant.
Parameters derived from the TEG tracing included time to initial fibrin clot formation (R) and the time from the beginning of clot formation until it reached a predefined degree of elasticity (K), with lower values indicating faster clotting. The angle between the line in the middle of the TEG tracing and the line tangential to the developing 'body' of the TEG (a-angle) was also assessed; a higher angle indicated faster clot formation kinetics. The maximum amplitude of the TEG tracing (MA), clot strength (G), and the elasticity constant (E) were also measured, with higher values indicating stronger clots.
Factor XIII activity
The presence of factor XIII activity in the respective fibrinogen components of EVICEL Fibrin Sealant (Human) and TISSEEL Fibrin Sealant was analyzed using a Berichrom F XIII kit (Dade Behring, Marburg, Germany). The EVICEL Fibrin Sealant (Human) samples were tested at a 1 : 20 dilution, while the TIS-SEEL Fibrin Sealant samples were tested at a 1 : 20 dilution and undiluted. Three batches from each kit were analyzed, and mean values of factor XIII concentrations were calculated. The lower limit of quantitation of the testing kit was 0.2 IU/ml.
Statistical analysis
Calculated mean Young modulus and tensile strength values and mean values for parameters obtained from the TEG test for EVICEL Fibrin Sealant (Human) and TISSEEL Fibrin Sealant were compared using a twosample, two-tailed, t-test with a significance level of 0.05.
Results

Young modulus and tensile strength testing
The mean Young modulus of the fibrin clots produced using EVICEL Fibrin Sealant (Human) was significantly higher than that of those produced using TISSEEL Fibrin Sealant (Table 1 ; Fig. 1 ). In addition, the mean tensile strength of the EVICEL Fibrin Sealant (Human) fibrin clots was approximately five times higher than that of the fibrin clots produced with TISSEEL Fibrin Sealant (Table 1) .
Thromboelastography
The TEG analysis results are shown graphically in Fig. 2 . The time to initial fibrin clot formation (R) and time to the predefined level of fibrin clot formation (K; for the samples diluted 1 : 20) were numerically shorter for EVI-CEL Fibrin Sealant (Human) compared with TISSEEL Fibrin Sealant, although these differences did not reach statistical significance (Table 2 ). In addition, the mechanical values measured by the TEG [maximum amplitude (MA), clot strength (G), and elasticity (E)] were numerically higher with EVICEL Fibrin Sealant (Human) than with TISSEEL Fibrin Sealant. Notably, significantly higher angle values were obtained with EVICEL than with TISSEEL Fibrin Sealant (P < 0.0001).
Factor XIII activity
The mean concentration of factor XIII in the fibrinogen component (tested at a 1 : 20 dilution) of EVICEL Fibrin Sealant (Human) was 9 IU/ml. For the fibrinogen component of TISSEEL Fibrin Sealant, no factor XIII was detectable at either the 1 : 20 dilution or in undiluted fibrinogen.
Discussion
Evaluations of mechanical, kinetic, and biochemical properties demonstrated that fibrin clots formed with EVICEL Fibrin Sealant (Human) have a higher resistance to stretching and are more capable of maintaining their structure against applied force than those formed with TISSEEL Fibrin Sealant. Moreover, the greater tensile strength of the EVICEL Fibrin Sealant (Human) fibrin clots indicates that those clots can withstand greater mechanical forces before yielding than the fibrin clots formed with TISSEEL Fibrin Sealant, which translates to stronger and more stable clots that are clinically less likely to give way to bleeding. Comparison of kinetic and mechanical properties using TEG analysis indicated that EVICEL Fibrin Sealant (Human) also facilitates more rapid development of fibrin clots than TISSEEL Fibrin Sealant.
The undetectable factor XIII concentrations in the TISSEEL Fibrin Sealant samples (tested at both a 1 : 20 dilution and undiluted) during direct assay indicated that there was very little covalent factor XIIIassociated cross-linking in the TISSEEL Fibrin Sealant. Because the fibrin sealants contained comparable amounts of fibrinogen, the superior clot strength and resilience obtained with EVICEL Fibrin Sealant Clot stability with EVICEL and TISSEEL Hickerson et al. 21 Strain-stress plots for EVICEL Fibrin Sealant (Human) and TISSEEL Fibrin Sealant. (Human) relative to TISSEEL Fibrin Sealant may therefore be largely attributed to the factor XIII activity.
Fibrinolysis and coagulation are greatly affected by the activity of factor XIII, which is the final enzyme activated in the coagulation cascade [15] . Following activation by thrombin, factor XIII leads to the formation of covalent cross-links between fibrin polymers, which strengthen fibrin clots [16] . In the absence of factor XIII, such cross-linking does not occur, resulting in a weaker, softer clot [17] . This evidence suggests that the presence of factor XIII in fibrin sealants may contribute to their clinical efficacy, especially when considered in the context of patients with low physiologic levels of factor XIII [15] . In fact, Dickneite and colleagues [17] found that fibrin sealants lacking detectable factor XIII were associated with soft and weak fibrin clots, as similarly demonstrated in the current study. In addition, Kheirabadi and colleagues [18] suggested that fibrin sealants with higher factor XIII may be associated with stronger fibrin clots than those with low levels of factor XIII.
Dickneite and colleagues [17] highlighted that the TIS-SEEL VH kit (an earlier version of TISSEEL: Vapor Heated, Solvent/Detergent Treated) does not contain detectable factor XIII, whereas the fibrin sealant kits sold in Europe and Japan by the same company [e.g. Tissucol and Tissucol Duo S (frozen)] contain approximately 10 IU/ml factor XIII [16] . Because manufacturing is performed using a similar process with plasma cryoprecipitate, it would appear that unlike Tissucol, TIS-SEEL Fibrin Sealant is not supplemented with plasmaderived factor XIII.
Whereas the current study provides evidence that may translate into positive clinical outcomes, there are currently no published studies of fibrin sealants showing a correlation between in-vitro product characteristics and clinical performance, nor are there any head-to-head clinical trials that might be extrapolated to confirm these in-vitro results. Additional rigorous studies are therefore necessary to explore and resolve these issues more fully.
In conclusion, the results of the present study demonstrate that, in vitro, EVICEL Fibrin Sealant (Human) produces a stronger and more resistant fibrin clot than TISSEEL Fibrin Sealant, which is likely the result of the higher factor XIII activity associated with the fibrinogen component of EVICEL Fibrin Sealant (Human). 
